-
公开(公告)号：US20190248777A1
公开(公告)日：2019-08-15
申请号：US16272506
申请日：2019-02-11
发明人： Ruichao Shen , Jun Ma , Guoqiang Wang , Xuechao Xing , Yat Sun Or
摘要： The present invention provides compounds of Formula (I): pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
-
公开(公告)号：US10253018B2
公开(公告)日：2019-04-09
申请号：US15988763
申请日：2018-05-24
发明人： Guoqiang Wang , Brett Granger , Ruichao Shen , Yong He , Xuechao Xing , Jun Ma , Jiang Long , Jing He , Bin Wang , Yat Sun Or
IPC分类号： C07D401/14 , C07D401/04 , C07D491/107 , C07D498/08
摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
公开(公告)号：US10144729B2
公开(公告)日：2018-12-04
申请号：US15597417
申请日：2017-05-17
发明人： Yat Sun Or , Jun Ma , Bin Wang , Yong He , Xuechao Xing , Ruichao Shen , Brett Granger , Jing He , Jiang Long , Guoqiang Wang
IPC分类号： A61K31/42 , C07D413/12 , C07D261/08
摘要： The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
-
公开(公告)号：US10080742B2
公开(公告)日：2018-09-25
申请号：US15497307
申请日：2017-04-26
发明人： Yat Sun Or , Ruichao Shen , Xuechao Xing , Brett Granger , Bin Wang , Jun Ma , Jing He , Yong He , Jiang Long , Guoqiang Wang
IPC分类号： C07D417/14 , C07D413/12 , C07D413/14 , A61K31/42 , A61K31/426 , A61K31/4725 , A61K31/545 , A61K31/64 , C07D261/08 , C07D275/04 , C07D277/62
CPC分类号： A61K31/42 , A61K31/426 , A61K31/4725 , A61K31/545 , A61K31/64 , C07D261/08 , C07D275/04 , C07D277/62 , C07D413/12 , C07D413/14 , C07D417/14
摘要： The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
-
公开(公告)号：US10034893B2
公开(公告)日：2018-07-31
申请号：US14169387
申请日：2014-01-31
发明人： Jay R. Luly , Jun Ma , Guoqiang Wang , Yat Sun Or
IPC分类号： C07H19/06 , C07H19/10 , C07H19/11 , A61K31/7072 , A61K45/06 , A61K31/13 , A61K31/7056 , A61K38/21
CPC分类号： A61K31/7072 , A61K31/13 , A61K31/7056 , A61K38/21 , A61K45/06 , C07H19/06 , C07H19/10 , C07H19/11 , A61K2300/00
摘要： In one aspect, the invention provides compounds represented by Formula I, and pharmaceutically acceptable salts, esters, stereoisomers, tautomers, solvates, and combinations thereof, pharmaceutical compositions comprising these compounds and the use of these compounds for treating a viral infection in a subject.
-
公开(公告)号：US20170334894A1
公开(公告)日：2017-11-23
申请号：US15597423
申请日：2017-05-17
发明人： Yat Sun Or , Yong He , Ruichao Shen , Xuechao Xing , Brett Granger , Bin Wang , Jun Ma , Jing He , Jiang Long , Guoqiang Wang
IPC分类号： C07D413/12
CPC分类号： C07D413/12 , A61K31/42
摘要： The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
-
公开(公告)号：US20170333399A1
公开(公告)日：2017-11-23
申请号：US15597431
申请日：2017-05-17
发明人： Yat Sun Or , Xuechao Xing , Ruichao Shen , Bin Wang , Brett Granger , Jun Ma , Jing He , Jiang Long , Yong He , Guoqiang Wang
IPC分类号： A61K31/42 , C07D225/04 , C07D213/127 , C07D261/08 , C07C317/38
CPC分类号： A61K31/42 , C07C317/38 , C07D213/127 , C07D225/04 , C07D261/08
摘要： The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR and methods for their preparation and use.
-
公开(公告)号：US20170304272A1
公开(公告)日：2017-10-26
申请号：US15497359
申请日：2017-04-26
发明人： Yat Sun Or , Bin Wang , Xuechao Xing , Ruichao Shen , Brett Granger , Jun Ma , Jing He , Yong He , Jiang Long , Guoqiang Wang
IPC分类号： A61K31/42 , A61K31/422 , C07D261/08 , C07D413/12
CPC分类号： A61K31/42 , A61K31/422 , C07D261/08 , C07D413/12
摘要： The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
-
公开(公告)号：US08846638B2
公开(公告)日：2014-09-30
申请号：US13897023
申请日：2013-05-17
发明人： Yat Sun Or , Jun Ma , Guoqiang Wang
IPC分类号： C07H19/00 , A61K31/70 , C07H19/14 , C07H19/23 , A61K45/06 , A61K31/7076 , C07H19/10 , C07H19/20 , C07H19/207 , A61K31/7064
CPC分类号： C07H19/207 , A61K31/7064 , A61K31/7076 , A61K45/06 , C07H19/10 , C07H19/14 , C07H19/20 , C07H19/23 , A61K2300/00
摘要： The present invention provides nucleoside phosphoramidate compounds of Formula I, where R1, R2a, R2b, R3, R4, R5a, R5b, R6, R7, R8a, R8b, M and W are as defined herein. The invention further includes pharmaceutical compositions comprising a compound of Formula I, methods of use of these compounds for treating a viral infection, and methods of producing these compounds.
摘要翻译： 本发明提供式I的核苷氨基磷酸酯化合物，其中R1，R2a，R2b，R3，R4，R5a，R5b，R6，R7，R8a，R8b，M和W如本文所定义。 本发明还包括含有式I化合物的药物组合物，这些化合物用于治疗病毒感染的方法，以及制备这些化合物的方法。
-
公开(公告)号：US20230174515A1
公开(公告)日：2023-06-08
申请号：US18073728
申请日：2022-12-02
发明人： Guoqiang Wang , Ruichao Shen , Jiang Long , Jun Ma , Xuechao Xing , Yong He , Brett Granger , Jing He , Bin Wang , Yat Sun Or
IPC分类号： C07D401/14 , C07D417/14 , C07D413/14 , C07D403/12 , C07D403/14 , C07D405/14
CPC分类号： C07D401/14 , C07D417/14 , C07D413/14 , C07D403/12 , C07D403/14 , C07D405/14
摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof:
which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
-
-
-
-
-
-
-
-
搜索结果
61 条记录 (耗时 0.047 秒)
